The honorable finance minister presented the budget for the financial year 2012-2013 on 16th March 2012. For the stock markets, it turned out to be a non-event. However, few budget proposals have affected various sectors in a small way. In this article, we discuss the impact of budget proposals on Indian pharmaceutical sector.
Major budget proposals that affected the pharma companies
The budget has proposed to tax all companies at the minimum alternate tax (MAT) of 18.5%. This will also include the partnerships firms based in the special economic zones (SEZ). Sun pharma will face a major hit as two of its facilities in Jammu and Sikkim enjoy benefits by avoidance of taxes as they do not pay the MAT.
The budget also increased the excise duty on drug formulation and Active Pharma Ingredients (API) from 5% to 6% and 10% to 12% respectively. However, the companies have manufacturing facilities in the SEZ area will not be affected as they do not have to pay the excise duties. According to us, this will not have much impact on most of the companies in the pharmaceutical space.
The budget has further announced to continue the deduction of 200% for in-house R&D for another 5 years. The previous scheme was supposed to expire on 31st March 2012 which now stands extended to 31st March 2017. Large pharma players like Dr Reddy, Sun Pharma, Glenmark and Biocon will thereby continue their tax benefits on R&D expenses.
Further there were certain announcements for capital expenditure on large hospitals and it is expected to benefit the players who are into managing hospitals.
Overall, the budget did not have anything encouraging for the pharmaceutical sector. However, the fact that there were no negative surprises itself has come as relief. The extension of deductions for the in-house R&D was a very good move and this will go a long way to incentivize the R&D within Indian pharmaceutical sector.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407